Caixa Capital BioMed

QIAGEN enters into agreement to acquire STAT-Dx, a Caixa Capital Risc portfolio company

STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes. The system was unveiled in April 2017 at the European Congress of Clinical Microbiology (ECCMID) and received a first CE-IVD marking in January 2018.

| Read more |

MedLumics, a company owned by “la Caixa” and Ysios Capital, closes a financing round of 34.4 million euros

• Medlumics has closed a round of financing round of 34,4 million euros to bring their main product into the market, AblaView, an atrial fibrillation treatment in the field of cardiac arrhythmias.
• Medlumics is a company dedicated to medical technology for the treatment of cardiac diseases, with products based on photonic energy.
• Caixa Capital Risc and Ysios Capital invested in Medlumics in 2012 to support the company in its development.
• This has been the largest round in the history of the medical technology industry in Spain, and one of the largest in Europe.

| Read more |

Caixa Capital Risc participates in BioSpain 2014

• BIOSPAIN is the largest biotech event organized in Spain and one of the largest in the world

• During the event, had participated more than 800 public and private entities coming from 36 different countries.

| Read more |

(Español) nLife Therapeutics recibe 350.000 dólares americanos de la Fundación Michael J. Fox para la investigación de la enfermedad de Parkinson

(Español) La financiación servirá para caracterizar el mecanismo de acción del compuesto principal de nLife, la NLF-PD-1233, en un modelo de enfermedad de Parkinson, así como para encontrar la dosis adecuada para el desarrollo clínico.

| Read more |

nLife cierra una inversión de 2 millones de euros para avanzar en el tratamiento contra el Parkinson

(Español) – “la Caixa”, a través de su gestora de capital riesgo, Caixa Capital Risc; Healthequity, el fondo de capital riesgo del Colegio Oficial de Médicos de Barcelona e Invercaria, invierten 2 millones de euros en nLife.

– nLife desarrolla nuevos tratamientos para enfermedades del sistema nervioso central que actúan en zonas seleccionadas del cerebro.

| Read more |